NEW YORK (GenomeWeb) – Myriad Genetics announced today that it has received positive coverage determinations for its EndoPredict breast cancer test from five Blue Cross Blue Shield affiliate plans.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.